People aged ≥6 months with medical conditions specified in this List. Medical conditions associated with an increased risk of influenza disease and severe outcomes are strongly recommended to receive annual influenza vaccine.

People with these specific medical conditions have a higher risk of influenza or severe outcomes from influenza .9-29

People who have received a transplant

People who have had a haematopoietic stem cell transplant or solid organ transplant and are receiving influenza vaccine for the first time after transplant are recommended to receive:

  • 2 doses at least 4 weeks apart the 1st time they receive influenza vaccine after the transplant
  • 1 dose each year after that
List. Specified medical conditions associated with increased risk of influenza disease and severe outcomes

Vaccine doses for people with the risk conditions in this list are funded under the NIP unless otherwise noted.


Immunocompromising conditions including: 

Functional or anatomical asplenia, including:

  • sickle cell disease or other haemoglobinopathies
  • congenital or acquired asplenia (for example, splenectomy) or hyposplenia

Cardiac disease, including:

  • cyanotic congenital heart disease
  • congestive heart failure
  • coronary artery

Chronic respiratory conditions, including:

  • suppurative lung disease
  • bronchiectasis 
  • cystic fibrosis
  • chronic obstructive pulmonary disease
  • chronic emphysema
  • Severe asthma (requiring frequent medical consultations or the use of multiple medicines)

Chronic neurological conditions, including:

  • hereditary and degenerative CNS diseases
  • seizure disorders
  • spinal cord injuries
  • neuromuscular disorders

Chronic metabolic disorders, including:

  • Type 1 or 2 diabetes
  • amino acid disorders
  • carbohydrate disorders
  • cholesterol biosynthesis disorders
  • fatty acid oxidation defects, lactic acidosis
  • mitochondrial disorders
  • organic acid disorders
  • urea cycle disorders
  • vitamin/cofactor disorders
  • porphyrias
Chronic renal failure
Long-term aspirin therapy in children aged 5 to 10 years
Chronic liver diseasea
Down syndromea
Obesity (body mass index ≥30 kg per m2) a
Children born less than 37 weeks gestationa
Harmful use of alcohola

a: Not funded under the NIP

Page history

Last updated: 
9 April 2020
Last reviewed: 
9 April 2020